Fumaric acid esters for the treatment of psoriasis, an angiogenesis-dependent disease

Authors

  • Melissa García Caballero Spain

Keywords:

esters, Fumaric acid, psoriasis, angiogenesis

Abstract

In 1959, the German chemist Schweckendiek postulated that psoriasis, a disease he himself suffered from, was caused by an alteration of the citric acid cycle and that an external addition of fumaric acid could reverse this pathology. Schweckendiek tried to test his hypothesis by ingesting fumaric acid esters (FAEs), as fumaric acid in its free form is highly irritating, and found that his psoriasis improved. Following the discovery of this capability of the FAEs, a pharmaceutical company named “Fumapharm” was born that began to market fumaric acid ester capsules whose dosage was one tablet three times a day, defining a maximum daily dose of 1.2 g.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Schweckendiek W. (1959). Heilung von psoriasis. Med Monatschr 13: 103- 104.

Ulrich M., Khusru A. (2005). Dimethylfumarate for psoriasis: more than a die- tary curiosity. Trends Mol Med 11: 43- 48.

Nieboer C., de Hoop D., van Loenen A.C., Langendijk P.N.J., van Dijk E. (1989). Systemic therapy with fumaric and derivates: new posibilities in the treat- ment of psoriasis. J Am Acad Dermatol 20: 601-608.

Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P., Was- silew S.W., Horn T., Kreysel H.W., Lutz G. (1994). Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30: 977-981.

Published

2009-12-20

How to Cite

García Caballero, M. (2009). Fumaric acid esters for the treatment of psoriasis, an angiogenesis-dependent disease. Encuentros En La Biología, 2(126), 59–60. Retrieved from https://revistas.uma.es/index.php/enbio/article/view/18527